Health

FDA Orders Vision Loss Warning on 12 GLP-1 Drugs

Is this a vital wake-up call for weight-loss drugs or does it fuel fear over an extremely rare risk?

3 hours ago·Updated 34 minutes ago

FDA Orders Vision Loss Warning on 12 GLP-1 Drugs

Story

Above: Weight loss medications on a weighing scale. Image credit: Michael Siluk/UCG/Universal Images Group/Getty Images

The Facts

The U.S. Food and Drug Administration (FDA) said Monday that makers of GLP-1 drugs must add information about a potential increased risk of a rare eye condition that can cause permanent vision loss to the warnings and precautions section of their labels.
New York Post
NBC
The FDA listed 12 drugs that must update their labeling, including Novo Nordisk's Ozempic, Wegovy and Rybelsus, as well as Eli Lilly's Mounjaro, Zepbound and Foundayo. Cases of the condition have been reported for all marketed GLP-1 products.
CNN
BioSpace
The FDA
Non-arteritic anterior ischemic optic neuropathy (NAION) stems from a sudden reduction or blockage of blood flow to the front of the optic nerve. Symptoms include painless vision loss in one eye, blurred vision, blind spots and distorted colors.
LiveNOW from FOX
The Hill
The FDA's review began after a 2024 study in JAMA Ophthalmology found that diabetes patients prescribed semaglutide were four times as likely to develop NAION. The agency cited the study's limitations and said further assessment was warranted.
New York Post
The Hill
The FDA
Regulators reviewed 126 clinical trials involving 78,217 patients who received a GLP-1 receptor agonist and found 6.4 NAION cases per 100,000 patient-years among GLP-1 users, compared with 3.8 per 100,000 patient-years for people on placebo or other glucose-lowering medications.
LiveNOW from FOX
BioSpace
Spokespeople for Novo Nordisk and Eli Lilly said patient safety is a top priority. Novo said the data do not establish a cause-and-effect relationship, while Lilly said it is evaluating the update and will respond to the FDA promptly.
CNN
NBC
Eli Lilly and Company

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

The FDA's warning is a serious wake-up call for the booming weight-loss drug industry. Patients deserve transparency about potentially irreversible vision loss, not marketing-driven reassurance. When widely prescribed medications carry emerging safety concerns, regulators must demand stronger evidence, clear warnings and accountability. No weight-loss benefit should come at the expense of eyesight.

Mario Nawfal on X

Ken D. Berry, MD on X

Narrative B

GLP-1 medications remain transformative tools in tackling obesity and diabetes. The FDA's warning concerns a potential link to an extremely rare eye condition, not proof of widespread harm. Strong health benefits should not be overshadowed by fear. Better monitoring, informed decisions and continued access matter more than unnecessary panic.

Avi Roy on X